2022 American Transplant Congress
Recurrent Cytomegalovirus and the Role of Secondary Prophylaxis in Heart and Lung Transplant Recipients
*Purpose: This study aimed to describe the incidence of cytomegalovirus (CMV) recurrence in heart and lung transplant recipients and the effect of secondary prophylaxis (SP)…2022 American Transplant Congress
Valganciclovir for the Prevention of CMV After Treatment of Rejection with Anti-Lymphocyte Depleting Antibodies in Kidney Transplant Recipients
University Health, San Antonio, TX
*Purpose: To evaluate efficacy and safety of valganciclovir for prevention of cytomegalovirus (CMV) after treatment of rejection with anti-lymphocyte depleting antibodies (ALA).*Methods: This single-center retrospective…2022 American Transplant Congress
Detection of CMV Mediated Sub-Clinical Rejection by Urine Biomarkers
1Nephrosant Inc, San Francisco, CA, 2UCLA, Los Angeles, CA, 3UCSF, San Francisco, CA
*Purpose: Research on early detection of Cytomegalovirus (CMV) mediated sub-clinical rejection (sAR) is in its nascence. This study explores the efficacy of urine-based biomarkers for…2022 American Transplant Congress
Avoiding Cytomegalovirus Mismatching in Deceased Donor Kidney Allocation System in the US
*Purpose: Cytomegalovirus (CMV) mismatch, donor-positive/recipient-negative serostatus (D+/R-), carries a high risk of developing CMV infection, graft failure mortality. The current kidney allocation system (KAS) does…2022 American Transplant Congress
Seasonal Variation of Cytomegalovirus Infection in Kidney Transplant Recipients
University of Wisconsin Health, Madison, WI
*Purpose: Studies conducted in the northern United States found cytomegalovirus (CMV) disease after liver transplantation follows a seasonal pattern, with increased incidence in Fall and…2022 American Transplant Congress
Preemptive Therapy in Cytomegalovirus (CMV) Seropositive Donor to Seronegative Recipient Liver Transplants
Transplant, Atrium Health's Carolinas Medical Center, Charlotte, NC
*Purpose: To evaluate if a preemptive therapy strategy can prevent CMV disease and induce CMV seroconversion.*Methods: Observational data collection for CMV D+/R- adult liver transplant…2022 American Transplant Congress
Maribavir (MBV) versus Investigator-Assigned Therapy (IAT) for Refractory Cytomegalovirus (CMV) Infection (with or without Resistance) in Solid Organ Transplant (SOT) Recipients: Subgroup Safety Analysis of a Phase 3 Study
*Purpose: In a Phase 3 study of MBV vs IAT (val/ganciclovir, foscarnet, or cidofovir) for refractory CMV infection (with/without resistance; R/R) in hematopoietic cell transplant…2022 American Transplant Congress
Incidence and Outcomes of CMV Infection in Pancreas Transplant with Thymoglobulin Induction: A Single Center Experience
Thomas Jefferson University Hospital, Philadelphia, PA
*Purpose: CMV infection is a major infectious complication in pancreas transplant recipients (PTR). Incidence of CMV viremia in PTR with thymoglobulin induction and it's effect…2022 American Transplant Congress
Letermovir for Prophylaxis of Cytomegalovirus After Solid Organ Transplantation: A Single-Center, Observational Study
*Purpose: Cytomegalovirus (CMV) infections cause significant complications post-transplant; however, prophylactic medications are often limited by toxicities. Letermovir is a novel terminase inhibitor specific to CMV…2022 American Transplant Congress
An Interventional Study Using Cell-Mediated Immunity to Guide Primary Prophylaxis for CMV Infection in Organ Transplant Recipients: A Multi-Center Study
*Purpose: There are limited interventional studies using CMV cell-mediated immunity to guide the duration of antiviral prophylaxis. We aimed to use CMV CMI to guide…
- 1
- 2
- 3
- …
- 33
- Next Page »